205 related articles for article (PubMed ID: 28661758)
1. Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).
Smith SG; Sestak I; Howell A; Forbes J; Cuzick J
J Clin Oncol; 2017 Aug; 35(23):2666-2673. PubMed ID: 28661758
[TBL] [Abstract][Full Text] [Related]
2. Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Sestak I; Smith SG; Howell A; Forbes JF; Cuzick J
Ann Oncol; 2018 Feb; 29(2):504-509. PubMed ID: 29126161
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
[TBL] [Abstract][Full Text] [Related]
4. Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.
Land SR; Walcott FL; Liu Q; Wickerham DL; Costantino JP; Ganz PA
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26615179
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
Cuzick J; Forbes J; Edwards R; Baum M; Cawthorn S; Coates A; Hamed A; Howell A; Powles T;
Lancet; 2002 Sep; 360(9336):817-24. PubMed ID: 12243915
[TBL] [Abstract][Full Text] [Related]
7. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
Sestak I; Harvie M; Howell A; Forbes JF; Dowsett M; Cuzick J
Breast Cancer Res Treat; 2012 Jul; 134(2):727-34. PubMed ID: 22588672
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Cuzick J; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A; Forbes JF;
Lancet Oncol; 2015 Jan; 16(1):67-75. PubMed ID: 25497694
[TBL] [Abstract][Full Text] [Related]
9. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
10. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
[TBL] [Abstract][Full Text] [Related]
11. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Veronesi U; Maisonneuve P; Rotmensz N; Bonanni B; Boyle P; Viale G; Costa A; Sacchini V; Travaglini R; D'Aiuto G; Oliviero P; Lovison F; Gucciardo G; del Turco MR; Muraca MG; Pizzichetta MA; Conforti S; Decensi A;
J Natl Cancer Inst; 2007 May; 99(9):727-37. PubMed ID: 17470740
[TBL] [Abstract][Full Text] [Related]
13. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Nelson HD; Smith ME; Griffin JC; Fu R
Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
[TBL] [Abstract][Full Text] [Related]
14. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
Chalas E; Costantino JP; Wickerham DL; Wolmark N; Lewis GC; Bergman C; Runowicz CD
Am J Obstet Gynecol; 2005 Apr; 192(4):1230-7; discussion 1237-9. PubMed ID: 15846210
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
16. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
17. Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.
Sestak I; Kealy R; Nikoloff M; Fontecha M; Forbes JF; Howell A; Cuzick J
Br J Cancer; 2012 Jul; 107(2):230-3. PubMed ID: 22735900
[TBL] [Abstract][Full Text] [Related]
18. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study.
Pandya KJ; Raubertas RF; Flynn PJ; Hynes HE; Rosenbluth RJ; Kirshner JJ; Pierce HI; Dragalin V; Morrow GR
Ann Intern Med; 2000 May; 132(10):788-93. PubMed ID: 10819701
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer: Study protocol clinical trial (SPIRIT Compliant).
Chan CWH; Miaskowski C; McCarthy A; Waye MMY; Yeo W; So WKW; Choi KC; Tsui SKW; Chan JYW
Medicine (Baltimore); 2020 Feb; 99(8):e19083. PubMed ID: 32080081
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study.
Day R; Ganz PA; Costantino JP
J Natl Cancer Inst; 2001 Nov; 93(21):1615-23. PubMed ID: 11698565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]